Taxotere Cytoxan and risk of febile neutropenia – pro
Santos et al reports: ” Data on G-CSF administration was available in 85 patients from our cohort. G-CSF was used as primary prophylaxis in 31 patients and in 13 patients as secondary prophylaxis, following a prior diagnosis of febrile neutropenia. Overall, fifteen women (15.8%) had a documented FN episode.”. This is consistent with other published reports on TC.Santos et al reports: ” Data on G-CSF administration was available in 85 patients from our cohort. G-CSF was used as primary prophylaxis in 31 patients and in 13 patients as secondary prophylaxis, following a prior diagnosis of febrile neutropenia. Overall, fifteen women (15.8%) had a documented FN episode.”. This is consistent with other published reports on TC.
Joao Paulo Velloso Medrado Santos et al, Febrile neutropenia risk with adjuvant TC (docetaxel and cyclophosphamide) regimen: Experience of Brazilian cancer centers. Journal of Clinical Oncology 32, no. 15_suppl
Vandenberg T, Younus J, Al-Khayyat S. Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis. Curr Oncol. 2010;17(2):2–3. doi:10.3747/co.v17i2.498